Biogen (BIIB) Is Betting Its Next Phase Of Growth On Four New Drugs

• Biogen (NasdaqGS:BIIB) is shifting its focus from older multiple sclerosis and Spinraza products to newer drugs in Alzheimer's, Friedreich’s ataxia, ALS, and depression.
• The company is leaning on recently launched therapies such as Leqembi, Skyclarys, Qalsody, and Zurzuvae to help offset pressure on its legacy franchises.
• This transition comes as competition from generics and biosimilars weighs on Biogen’s established revenue base.

Biogen sits at the center of several high-profile treatment areas, from multiple sclerosis to neurodegenerative and rare diseases. As competition increases and pricing pressure builds on its older products, the company is relying more on its newer launches to carry a larger share of overall revenue. For investors, this mix shift highlights how much of Biogen’s future story is now tied to newer therapies rather than long-standing blockbusters.

The key question is how effectively drugs like Leqembi, Skyclarys, Qalsody, and Zurzuvae can build scale as legacy sales come under strain. The balance between declining older products and the uptake of new ones is likely to influence how investors view Biogen’s risk profile, capital allocation choices, and research priorities over the next several years.

Stay updated on the most important news stories for Biogen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Biogen.

We've flagged 1 risk for Biogen. See which could impact your investment.

Quick Assessment

• ⚖️ Price vs Analyst Target: Biogen trades at US$216.03 versus a US$220.25 analyst target, a gap of about 2%.
• ✅ Simply Wall St Valuation: Shares are flagged as trading 48.9% below an estimated fair value.
• ✅ Recent Momentum: The stock is up 9.7% over the last 30 days.

There's only one way to know the right time to buy, sell or hold Biogen. Head to Simply Wall St's company report for the latest analysis of Biogen's Fair Value.

Key Considerations

• 📊 This product transition means more of Biogen’s investment case now rests on execution in Alzheimer's, Friedreich’s ataxia, ALS, and depression rather than legacy multiple sclerosis and Spinraza revenues.
• 📊 Track launch metrics for Leqembi, Skyclarys, Qalsody, and Zurzuvae, plus how quickly these therapies contribute to revenue versus ongoing erosion in older products.
• ⚠️ One flagged risk is that large one off items can affect reported earnings, which can make it harder to judge how smoothly this portfolio shift is progressing.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Biogen analysis. Alternatively, you can check out the community page for Biogen to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com